The psychedelic mystical experience in the human encounter with death
This early review (1969) investigates the mystical experience and its relationship to death, with a focus on terminal cancer patients who had received psychedelics at that time. The correlation between the profoundness of the experience and therapeutic (long-term/non-acute) outcomes is also discussed.
Abstract
From the introduction: This Spring I received a long-distance telephone call from Dean Samuel Miller, who invited me to give this year's Ingersoll Lecture on human immortality. Three days later, Dean Miller was dead. When I heard the sad news, I, as many of you no doubt, began to think about the way he had influenced me, especially during my theological training here at Harvard Divinity School. One of my most vivid memories was a point which he emphasized in his class on Religion and Literature. Sam Miller felt strongly that in our modern 20th century two of the most profound and important experiences of human life are becoming more and more insulated from everyday existence. These two experiences, birth and death, have the potential for affecting the character and quality of the rest of life. But in each instance, they are falling victim to modern technological efficiency and adding to the process of dehumanization rather than counteracting it.
Research Summary of 'The psychedelic mystical experience in the human encounter with death'
Introduction
Pahnke frames the problem in cultural and clinical terms: in modern societies the pivotal experiences of birth and death have been increasingly medicalised and insulated, with death in particular often managed in ways that avoid honest interpersonal engagement. For terminal cancer patients this tendency, the author argues, contributes to fear, isolation, depression, and a loss of opportunities for meaningful psychological and relational work in the face of mortality. Against that background, the paper reports a small, exploratory programme that used LSD-assisted psychotherapy to attempt to alter the dehumanising trajectory often seen around dying. The stated aim was to maximise the chance of producing a psychedelic mystical experience (a specific peak-type response) within a controlled therapeutic context and to assess whether such experiences could reduce fear, depression, and isolation and improve the quality of patients' final weeks. This work is presented as pilot research rather than a definitive clinical trial, and its clinical and existential relevance is emphasised.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Topics
- APA Citation
Pahnke, W. N. (1969). The psychedelic mystical experience in the human encounter with death. Harvard Theological Review, 62(1), 1-21. https://doi.org/10.1017/S0017816000027577
Cited By (28)
Papers in Blossom that reference this study
Kirlić, N., Atli, M., Mistry, S. et al. · Journal of Clinical Psychopharmacology (2025)
Peacock, C., Mascaro, J. S., Brauer, E. et al. · PLOS ONE (2024)
Ragnhildstveit, A., Khan, R., Seli, P. et al. · Frontiers in Psychiatry (2023)
Kangaslampi, S. · Journal of Psychedelic Studies (2023)
Devenot, N., Seale-Feldman, A., Smith, E. et al. · Kennedy Institute of Ethics Journal (2022)
Moreton, S. G., Burden-Hill, A., Menzies, R. E. · Clinical Psychologist (2022)
McCulloch, D. E-W., Madsen, M. K., Jensen, P. S. et al. · Frontiers in Pharmacology (2022)
Maia, L. O., Massarentti, C. M., Tófoli, L.F. · Psychopharmacology (2022)
Sumner, R. L., Chacko, E., Mcmillan, R. et al. · Journal of Psychopharmacology (2021)
Schmidt, T. T., Reiche, S., Hage, L. T. et al. · Scientific Reports (2020)
Show all 28 papersShow fewer
Nayak, S., Johnson, M. W. · Pharmacopsychiatry (2020)
Kangaslampi, S., Hausen, A., Rauteenmaa, T. · Journal of Psychoactive Drugs (2020)
Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)
Moreton, S. G., Szalla, L., Menzies, R. E. et al. · Psychopharmacology (2019)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Reiche, S., Hermle, L., Gutwinski, S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Elsey, J. W. B. · Drug Science Policy and Law (2017)
Letheby, C., Gerrans, P. · Neuroscience of Consciousness (2017)
Millière, R. · Frontiers in Human Neuroscience (2017)
Haden, M., Emerson, B., Tupper, K. W. · Journal of Psychoactive Drugs (2016)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
Kirchner, K. · Journal of Psychopharmacology (2014)
Schenberg, E. E. · Sage Open Medicine (2013)
Grob, C. S., Bossis, A. P., Griffiths, R. R. · Preprints (2013)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Kurland, A. A. · Journal of Psychoactive Drugs (1985)
Goodman, L. E., Grof, S., Kurland, A. A. et al. · Journal of Transpersonal Psychology (1972)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.